Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Achaogen target raised to $28 at Stifel — Manufacturing disclosure creates both volatility & opportunity (25.25)Stifel raises their AKAO tgt to $28 from $27. Management's 4Q16 earnings announcement/call included a surprising number of incremental updates given the proximity to the recent R&D Day Event — including positive regulatory feedback on a development path forward for C-Scape, the departure/transition of the Chief Medical Officer, and the issuance of a FDA Warning Letter to one of the co's manufacturing/supply chain constituents (Pfizer/Hospira, a fill-site facility for plazomicin). And while they understand investor perception of the latter is likely negatively influenced by recent manufacturing impediments experienced by a number of sponsors (including antibiotic sponsors), they're inclined to believe management's confidence in unchanged plazomicin regulatory submission timelines and lack of urgency around the need to initiate the technology transfer process required to bring an additional fill-site online implies this was really more of an attempt at full disclosure. They'd <strong>look to be opportunistic on any related weakness.</strong></td> </tr></table>"